Fischer MV partners with BAV to launch livestock and aquaculture vaccines in India

New Delhi: Fischer Medical Ventures Ltd (Fischer MV) has announced a strategic partnership with Bio Angle Vacs Sdn Bhd (BAV) to introduce breakthrough vaccines for livestock and aquaculture into the Indian market. This collaboration marks a significant step in advancing food security and health by reducing mortality rates in animals.

The partnership between Fischer MV and BAV will focus on establishing a production facility in India to serve local and Middle Eastern markets, leveraging India’s position as a leader in livestock and marine populations. 

One of the BAV’s flagship innovations is the Spray Technology Vaccine (STVAC), developed by Prof. Mohd Zamri Saad from Universiti Putra Malaysia. STVAC uses advanced recombinant technology and intranasal administration to elicit both mucosal and systemic immune responses, enhancing protection against bacterial infections, particularly in goats and sheep, significantly reducing mortality rates from diseases like pneumonic pasteurellosis to below 5%.

The collaboration will also introduce other BAV products, such as SEABIOBROWN, a symbiotic feed enhancer for shrimp that combines prebiotics and probiotics to prevent diseases like acute hepatopancreatic necrosis disease (AHPND) and vibriosis. Additionally, products like VIVAC, a Vibrio vaccine for Asian marine fish cultures, and AQUABOOSTER, an oral feed vaccine for freshwater fish, will enhance survival rates and combat common bacterial infections, providing a significant boost to small and medium-sized fish farmers.

Ravindran Govindan, Executive Chairman & MD of Fischer MV, expressed, “This collaboration with BAV is our commitment in food security, starting from India with the 2nd largest sheep & goat population of about 223 million, and where food security is a growing issue. With Fischer MV’s expertise in MedTech solutions, robust resources, and strategic network, we look forward to bring BAV’s ground-breaking, cost-effective animal vaccines and products to the rest of the world to improve our food safety.”

Noor Shazreena Ishak, CEO of BAV, shared, “In view of the growing demand for preventive healthcare in the animal world, we are committed to offer easy, cost-effective and, trustworthy solutions to relief the stress of our livestock and aquaculture and greatly improve the ROI of farmers. Through this collaboration with Fischer MV, we will have stronger science, tech and marketing support to meet the global demand for quality and affordable animal vaccines, and ultimately help reduce the burden of animal diseases worldwide.”

Bio Angle Vacs’ state-of-the-art facility in Malaysia is fully operational to manufacture its range of vaccines to meet global demand. BAV has developed a range of innovative vaccines that have already secured USD 83 million in annual sales contracts from countries like China, Nigeria, Kenya, Chad, Uganda, Uzbekistan, and Indonesia. 

Fischer MV, known for its expertise in medical diagnostic and imaging technologies, aims to extend its commitment to preventative healthcare through this venture.

According to the Food and Agriculture Organization (FAO), the global animal vaccines market is valued at USD 18.8 billion in 2024. The aquaculture vaccine market, valued at over USD 201.5 million in 2020, is expected to grow at a 4.3% CAGR by 2027 due to increasing bacterial infections in fish species. The global freshwater fish market, estimated at USD 149.895 billion in 2019, is projected to reach USD 183.544 billion by 2026, highlighting the substantial potential for growth in this sector.